Watch · 54/100 · medium confidence

SILGAN HOLDINGS INC (SLGN) — Council Assessment

🟡 WATCH · Score 54/100 · medium confidence

A cheap, cash-generative but leverage-heavy, low-ROIC packaging stalwart trading at its 52-week high — fairly valued at best, not a compounder.

As of 2026-06-26. 18 lenses weighed in, 0 abstained. Sources: 6 filings, 17 news, 15 discussion, 1 earnings_call.

360 narrative — news & sentiment digest

SLGN Investment Briefing

Management Commentary (Q3 2025 Earnings Call)

Guidance & Outlook Revision Management lowered Q4 2025 guidance materially, projecting adjusted EPS of $0.62–$0.72 (vs. prior expectations), citing a $25M headwind from volume declines and inventory reductions. Despite this, full-year 2026 guidance (released Feb 2026) sits at $3.70–$3.90 adjusted EPS (roughly 2% growth vs. 2025's $3.72), with free cash flow expected at ~$450M.

Key Segment Trends

Dispensing & Specialty Closures (~65% of DSC sales, 75% of EBITDA post-Vayner): Delivered record Q3 adjusted EBIT with 40% dispensing product growth, but Q4 volumes expected to decline mid-single digits. Management blamed consumer bifurcation—high-end fragrance/beauty continuing strong (15% Q3 organic growth, double-digit Q4 expected), but personal care and home care products faltering as lower-income consumers delay discretionary purchases (hard surface cleaners, hand lotions). Vayner integration completed on track.
Metal Containers: Delivered stable Q3 with 4% volume growth (+10% in pet food, resilience in fruit/vegetable). Expected mid-single-digit full-year growth. Management emphasized ~90% of contracts are long-term (5–10 years) with blue-chip, investment-grade customers. One large fruit/vegetable customer filed for bankruptcy mid-quarter but volumes performed as expected; management sees potential $10M cost-reduction opportunity if volumes remain depressed, and anticipates capacity investments in 2026 for pet food growth.
Custom Containers: Record adjusted EBIT, up 15% YoY, driven by cost reductions and price/mix gains. Unit volumes flat as expected after exiting lower-margin business; excluding divestitures, volumes grew 4%.

Consumer & Market Commentary Adam Greenlee (CEO) explicitly described a "bifurcation" in North American consumer behavior: high-income consumers purchasing premium products (fragrance, specialty closures), while lower/mid-income consumers stretched by inflation and muted wage growth are trading down to shelf-stable foods, delaying non-essentials. He distinguished this from the broad post-pandemic destocking of 2023, framing it as specific to personal care/home care weakness, not systemic. Sports drink volumes recovered—Q2–Q3 challenges attributed to poor weather limiting drink occasions, not category decay.

Capital Allocation & Leverage

Returned >$120M via dividends and share buybacks in first nine months; opportunistically repurchased ~$60M of shares in Q1 believing stock undervalued.
On track to reduce net leverage to "near the midpoint of our range, just over 12 months" post-Vayner (closed mid-2024).
Maintaining $430M free cash flow guidance for 2025 despite Q4 earnings headwind, via proactive inventory reduction and cost actions.

Tone & Candor Management acknowledged miss vs. prior DSC revenue guidance (guided mid-to-high 20s%, delivered ~22%) and late visibility (late September, forecast clarity only in early October). Defended decision not to pre-announce, citing timing of customer forecasting cycle. Otherwise detailed and transparent on bifurcated demand, specific category weakness, and remedial actions.

Recent Developments

Q4 2025 Guidance Cut (Nov 2025 call): Adjusted EPS forecast reduced to $0.62–$0.72 from prior expectations; cited $25M headwind ($20M DSC, $5M custom containers) from volume declines and inventory management.
2026 Full-Year Guidance (Feb 2026): Adjusted EPS $3.70–$3.90 (vs. $3.72 in 2025, ~2% midpoint growth); free cash flow ~$450M; Q2 2026 EPS guidance $0.92–$1.02.
Q1 2026 Results (Apr 2026): Beat expectations; company raised full-year 2026 adjusted EPS to $3.73–$3.93 and confirmed FCF at ~$450M.
Dividend Continuity: Maintained quarterly dividend, extending 89-quarter streak (mentioned in May 2026 news).

Bull Narrative

Strong Dispensing Portfolio: High-value, high-margin dispensing products (especially fragrance/beauty and healthcare/pharma) showing sustained double-digit organic growth; Vayner acquisition (completed mid-2024) integrating successfully and expected to contribute meaningfully to 2026 earnings.
Metal Containers Resilience & Growth: ~90% of volume under long-term contracts with blue-chip, investment-grade customers; pet food segment delivering 10% growth in 2025 with further capacity investments planned for 2026. Bankruptcy of one major customer appears contained and presenting cost-reduction upside.
Leveraged FCF & Deleveraging: Management targeting net leverage to midpoint of guidance range (~12 months post-Vayner); $450M FCF guidance implies strong cash generation despite 2025 earnings volatility.
Valuation: Trading at <10× trailing 12-month EPS (noted by analyst George Staffos on Q3 call), described as lowest in ~20 years; implies significant upside if consumer bifurcation proves transient and DSC returns to mid-single-digit organic growth.
Q1 2026 Beat & FY Raise: Early 2026 results exceeded expectations, prompting management to raise full-year EPS guidance to $3.73–$3.93 from prior $3.70–$3.90, signaling momentum recovery.
Consolidation Tailwind in Custom Containers: Fragmented market; ongoing industry consolidation and Silgan's differentiated service model positioning it as attractive M&A partner or standalone value creator.

Bear Narrative

Demand Visibility & Execution Risk: Late-cycle discovery of DSC weakness (late Sept, forecast only early Oct) raises questions about forward visibility and management's ability to forecast. Analyst George Staffos pressed on why pre-announcement wasn't made; management's defense (customer timing) credible but doesn't fully allay concerns.
Consumer Bifurcation Uncertainty: While management frames 2025 weakness as isolated, the extent and duration of lower-income consumer pullback in personal care/home care remains unquantified. No clear inflection point articulated for recovery; 2026 guidance implies only modest growth, suggesting lingering caution.
DSC Growth Deceleration: After years of M&A-driven growth (Vayner), organic growth in high-value dispensing is described only as "at least mid-single-digit"—below historical rates and the market's expectations. Food & beverage closures (sports drinks) still vulnerable despite weather narrative.
Leverage & Balance Sheet: Despite leverage guidance, debt increased from Vayner; any earnings miss or extended consumer weakness could pressure credit metrics and dividend sustainability (though 89-quarter streak suggests commitment).
Peer Dynamics: Management noted a competitor exiting the sports beverage closure market, suggesting structural headwinds in beverages even if specific 2025 weakness was weather-driven.
Retail Skepticism: One retailer (Stonky_Mcprofitface, Stocktwits, Apr 2026) expressed frustration with underperformance since 2021 (+3.5% total return), criticizing CEO compensation and board effectiveness as misaligned with results.

Retail Sentiment

Mixed to cautiously optimistic, with conviction low:

Neutral-to-Bullish Technical: Multiple posts on Stocktwits and TradingView cite "strong value play" at $36–$40 range, with options traders targeting 50–70% upside on call spreads (Feb–Aug 2026 expirations). Peloswing noted "multiple bottoms" at $36–$37 as potential support.
Dividend Appeal: Extended dividend streak (89 quarters) and yield cited as attractive, though Sahm article (Jun 2026) notes scrutiny of "risk-reward balance" given valuation and earnings volatility.
Skepticism on Growth: Stonky_Mcprofitface (Apr 2026) critical of CEO pay relative to performance; broader forum tone suggests disappointment that company isn't "winning big and often" despite management rhetoric.
Limited Depth: Retail discussion sparse; most chatter around options plays or dividend yield rather than deep fundamental conviction. No major retail thesis evident.

Caveats

Earnings Call Transcript Quality: The Q3 2025 call transcript contains apparent OCR/transcription errors ("Sylvan" vs. Silgan, "Police Chevrolet" for unclear executive name, garbled Q&A sections). Quotes extracted are likely paraphrased accurately but should be verified against official version if critical to decision.
2026 Guidance Caveats: Full-year 2026 EPS guidance of $3.70–$3.90 (later raised to $3.73–$3.93) represents only ~2% growth at midpoint; management explicitly flagged it will be "a little more conservative" than historical practice, reflecting uncertainty from 2025 volatility and discrete items (bankruptcies, weather). No Q1 or Q2 detail beyond Q2 EPS range ($0.92–$1.02).
Consumer Bifurcation Quantification: While management articulates a compelling narrative of low-income consumer stress, no granular data on segment exposure (% of DSC revenue in personal care, home care) or elasticity is provided in the transcript. The $25M Q4 headwind and expected recovery timing remain largely qualitative.
Vayner Contribution Opacity: Management noted difficulty isolating Vayner P&L post-integration; makes it hard for investors to assess organic vs. inorganic growth in DSC or validate the acquisition thesis independently.
Peer & Sector Context Missing: No discussion of competitive positioning, pricing power, or industry growth rates; hard to assess whether Silgan's mid-single-digit guidance is in line with packaging sector or reflects share losses.
Retail Sentiment Thin: Only a handful of Stocktwits/forum posts; not representative of institutional or broad retail conviction.

Bull case

The valuation lenses (Damodaran referee 72, Greenwald 72, Christensen referee 78) see a genuinely cheap, forecastable business: P/FCF of 11.6x on ~$423M real FCF (guided $450M in 2026), a DCF intrinsic of $64.31 vs. $46.23 (~39% upside) with even the bear case ($48.10) above current price. FCF exceeds GAAP net income (forensically clean), ~90% of metal container volume sits under 5-10 year contracts with investment-grade customers, an 89-quarter dividend streak signals discipline, the dispensing/beauty segment is growing double-digits, and deleveraging plus a Q1 2026 beat suggest the 2025 consumer bifurcation weakness was transient. The physical-manufacturing moat is orthogonal to AI disruption. Embedded market expectations are modest (~2% perpetual growth), a low bar to clear.

Bear case

Nearly every quality lens (Akre 32, Smith 32, Fisher 28, Druckenmiller 28, Schloss 32) flags the same structural problem: ROIC of 4.74% is BELOW the 7% WACC — the business destroys value on incremental capital, and unlevered returns are poor. ROE of 12.7% is entirely leverage-assisted (D/E 1.63x, $3.72B LTD, ~6.2x net debt/FCF). Revenue CAGR is 0.37% over three years with only ~2% EPS growth guided — no reinvestment runway, no earnings inflection. The DCF is 80.5% terminal value on a 2.5% growth assumption that exceeds actual growth by 6x, so the '39% upside' is fragile. Graham/Schloss note the balance sheet fails conservative tests and the stock trades AT its 52-week high — Mr. Market is optimistic, not offering a bargain.

Dissent — where the council disagrees

The council splits sharply along methodology lines. The valuation and disruption referees (72/72/78) call this a Pass on cheapness and durability, while the quality purists (Akre, Smith, Fisher, Munger, Druckenmiller — all 28-32) call it an Avoid because ROIC below WACC means the terminal-value math that drives the DCF upside is mathematically overstated. This tension is decisive: the same 80.5% terminal-value dependence that makes the DCF look attractive is exactly what makes it unreliable when ROIC<WACC. The forensic short-seller (62, Pass) sides with 'not a fraud but a possible value trap' and flags a ~36% gap between adjusted EPS ($3.72) and implied GAAP EPS (~$2.73) that no lens fully reconciled. The centrists (Buffett, Marks, Klarman, Greenblatt, Lynch, Dalio, Mauboussin — all 52-58 Watch) converge on 'fair business at a fair price, thin margin of safety given leverage.' The weight of applicable evidence lands squarely in Watch: real cash but poor economics, cheap but not cheap enough for the leverage, at a price high rather than a low.

Key risks

ROIC (4.74%) below WACC (7%) — incremental capital destroys value and undermines the DCF terminal-value math
Elevated leverage: $3.72B LTD, D/E 1.63x, ~6.2x net debt/FCF with only 5.5% operating margin cushion
DCF is 80.5% terminal value on 2.5% growth vs. 0.37% actual CAGR — highly sensitive to assumptions
Consumer bifurcation in DSC (personal/home care) with unquantified recovery timeline; management had late Q4 2025 visibility
~36% gap between adjusted EPS ($3.72) and implied GAAP EPS (~$2.73) needs itemization
Stock at 52-week high — no bargain entry, optimism already priced
Serial debt-funded M&A (Vayner) with opaque organic vs. inorganic contribution

Catalysts

Continued deleveraging toward midpoint of range improving equity value and flexibility
DSC/dispensing organic re-acceleration as consumer bifurcation normalizes
Pet food capacity investments generating returns above cost of capital
Sustained $450M+ FCF supporting buybacks below intrinsic value and dividend growth
Multiple re-rating if ROIC migrates above WACC as Vayner synergies mature

DCF valuation (finance-expert model)

two-stage DCF, Gordon terminal value, CAPM-weighted WACC.

Intrinsic value: $64.31/share vs price $46.23 → +39% (bear $48.1 · base $64.31 · bull $72.66).

Step	Value
Base free cash flow	$423M
FCF growth (yrs 1-5)	2.0% (revenue CAGR)
WACC (β 0.707)	7.0%
Terminal growth	2.5%
PV of explicit FCF	$1.8B
PV of terminal (residual) value	$7.6B (80% of EV)
Enterprise value	$9.4B
less Net debt	$2.6B
= Equity value	$6.8B
/ Shares (105M) = intrinsic/share	$64.31

Short-sell evaluation

🚫 AVOID SHORTING

Despite low ROIC, near-zero growth, and heavy leverage, SLGN is a poor short. The forensic short-seller (62) explicitly concludes this is 'not a clean short' — earnings quality is genuinely good (OCF $730M >> net income $288M; FCF exceeds GAAP earnings), there is no fraud signal, and the business generates ~$423M of real, contracted, defensive cash flow. The stock is already cheap (11.6x P/FCF, 0.75x sales) with a DCF bear case ($48) roughly at the current price — meaning the downside is largely priced in and the valuation asymmetry favors longs, not shorts. Low beta (0.71), an 89-quarter dividend streak, ongoing buybacks, and non-discretionary end markets provide a floor and squeeze/carry risk. Shorting a fairly-to-cheaply valued cash generator at a small structural flaw is exactly the setup that kills shorts.

Pros (the short could work)

ROIC (4.74%) below WACC and near-zero revenue growth (0.37% CAGR) support a value-trap narrative
High leverage (~6.2x net debt/FCF, D/E 1.63x) magnifies downside if FCF compresses or rates rise
~36% adjusted-vs-GAAP EPS gap could unwind if 'adjustments' prove recurring
DCF is 80.5% terminal value — a modest cut to terminal growth removes the apparent upside
Consumer bifurcation and one customer bankruptcy point to potential further volume/earnings misses

Cons (what kills the short)

Forensically clean: OCF and FCF both exceed net income — no earnings-inflation red flag
Already cheap (11.6x P/FCF, bear-case DCF ~$48 near current price) — limited valuation downside
Defensive, contracted cash flows (~90% metal volume under 5-10 yr contracts) provide a floor
Low beta (0.71), 89-quarter dividend streak, and active buybacks create squeeze/carry drag
Deleveraging trajectory and Q1 2026 beat/raise argue fundamentals are stabilizing, not deteriorating
Unlimited-downside asymmetry on shorting a stable cash generator with income-investor support

Council scorecard

Lens	School	Stance	Score	Conf
AI & Disruption Referee (Christensen-style)	referee	🟢 pass	78	high
Valuation Referee (Damodaran-style)	referee	🟢 pass	72	medium
Bruce Greenwald	value	🟢 pass	72	medium
Forensic Short-Seller (Chanos/Einhorn-style)	referee	🟢 pass	62	medium
Joel Greenblatt	value	🟡 watch	58	medium
Howard Marks	risk	🟡 watch	58	medium
Ray Dalio	risk	🟡 watch	55	medium
Benjamin Graham	value	🟡 watch	55	medium
Warren Buffett	quality	🟡 watch	52	medium
Seth Klarman	value	🟡 watch	52	medium
Peter Lynch	growth	🟡 watch	52	medium
Charlie Munger	quality	🟡 watch	52	medium
Michael Mauboussin	quality	🟡 watch	52	medium
Chuck Akre	quality	🔴 avoid	32	high
Walter Schloss	value	🔴 avoid	32	high
Terry Smith (Fundsmith)	quality	🔴 avoid	32	high
Stanley Druckenmiller	risk	🔴 avoid	28	high
Philip Fisher	growth	🔴 avoid	28	high

Member reasoning

AI & Disruption Referee (Christensen-style) — 🟢 pass · 78/100 · high confidence

Silgan Holdings manufactures physical packaging — metal containers, dispensing closures, and plastic containers — for consumer staples, pet food, beauty/fragrance, healthcare, and home care. The core job the company does for its customers is fabricating and supplying engineered physical vessels and dispensing mechanisms at scale, under long-term contracts, with manufacturing consistency, regulatory compliance, and supply-chain reliability. AI and automation cannot manufacture a metal soup can or a precision fragrance pump; the job is atoms, not bits. This is one of the cleaner cases where the Christensen displacement mechanism simply does not apply to the product itself. The obsolescence question resolves quickly: no AI system can substitute for a tin-plated steel cylinder or a polypropylene closure. The demand for the physical artifact cannot be disintermediated by a language model or a generative AI system. That said, AI is a real factor on several second-order dimensions that must be scored honestly. On the cost/operations side, AI-driven manufacturing optimization, predictive maintenance, computer vision for quality control, and supply-chain AI are genuine tailwinds — Silgan operates high-volume, capital-intensive plants where marginal efficiency gains matter, and adoption of these tools (whether by Silgan or by competitors) will compress margins industrywide if not adopted, or expand them if Silgan leads. There is no evidence from the filings or earnings call that Silgan is materially ahead or behind peers here, which is neutral. On the demand side, the real AI-adjacent risk is behavioral: if generative AI accelerates the shift to e-commerce and direct-to-consumer (DTC) models, packaging formats and dispensing requirements may shift faster — but this is a product-mix evolution, not obsolescence. Silgan's dispensing and specialty closures segment actually benefits from premiumization in beauty and fragrance, a trend AI-driven personalization in beauty (Sephora, L'Oreal, etc.) arguably reinforces rather than undermines. A subtler threat: AI-assisted formulation and product development by CPG customers could compress product cycles and increase SKU complexity, raising tooling and changeover costs for Silgan. This is manageable but not trivial. The hyperscaler capture question is irrelevant — Amazon, Google, and Microsoft have no plausible path to disintermediate a tin can manufacturer. The intermediary/disintermediation test is inapplicable; Silgan is not a matching platform or a toll-taking aggregator. It is a manufacturer with physical assets, long-term contracts (~90% of metal container volume under 5-10 year agreements with investment-grade customers), and significant switching costs (tooling qualification, regulatory approval for food/pharma packaging, capital co-investment). These moats are orthogonal to AI disruption. The one area warranting a 'watch' flag: if AI-driven consumer behavior shifts accelerate the decline of certain legacy formats (shelf-stable canned goods losing share to fresh/refrigerated as AI-personalized meal kits grow), Metal Containers could face secular volume headwinds. But this is a slow-moving trend already visible in fundamentals (revenue CAGR of 0.37% over 3 years), not an AI-specific acceleration risk. Management's earnings call commentary shows zero engagement with AI as either a threat or an opportunity — which for a physical manufacturer is not denial but appropriate irrelevance. No red flags are triggered.

Key points

Core product is physical manufacturing (metal containers, dispensing closures, plastic containers) — AI cannot substitute for the fabricated artifact; the obsolescence mechanism does not apply
~90% of metal container volume under long-term (5-10 year) contracts with investment-grade CPG customers creates structural switching costs AI cannot erode
Dispensing and specialty closures in fragrance/beauty/pharma benefit from premiumization trends that AI-driven personalization in consumer goods likely reinforces, not disrupts
AI as operational tailwind: manufacturing optimization, predictive maintenance, and quality-control AI can improve margin efficiency — neutral to mildly positive if Silgan adopts at industry pace
No intermediary/disintermediation risk: Silgan is a capital-intensive manufacturer, not a matching platform or toll-taking aggregator; hyperscaler bundle risk is inapplicable
Falsifiable: evidence of AI displacement would require a substitute physical manufacturing technology (not AI per se) displacing tin/polymer containers — e.g., smart packaging or active packaging formats disrupting passive containers; this is a 15-20 year horizon at earliest

Red flags

Revenue CAGR of 0.37% over 3 years suggests the legacy Metal Containers segment faces secular volume pressure from changing consumer diets — AI-personalized meal kits and fresh-food delivery could modestly accelerate this, though it is not AI-specific
SKU proliferation driven by AI-assisted CPG product development could increase tooling complexity and changeover costs, compressing margins in custom containers
Management shows no engagement with AI as operational opportunity in public communications — risk of being a late adopter of manufacturing AI relative to peers, ceding efficiency advantages

Valuation Referee (Damodaran-style) — 🟢 pass · 72/100 · medium confidence

Silgan Holdings is a mature, asset-heavy packaging company with forecastable cash flows — precisely the kind of business where a story-to-numbers DCF is meaningful rather than false precision. The provided DCF intrinsic value of $64.31/share vs. current price of $46.23 implies ~39% upside, and even the bear-case DCF of $48.10 sits modestly above today's price. Let me stress-test the key inputs. WACC of 7.0% is defensible: beta of 0.71, blended cost of equity ~7.84%, and a packaging business with stable, contracted revenue justifies a below-average cost of equity. Terminal growth of 2.5% is right at the boundary of acceptability — slightly aggressive versus a 4–4.25% risk-free rate environment (real GDP ~2%, nominal closer to 4–4.5%), and this is the model's key vulnerability. If terminal growth is trimmed to 2.0%, intrinsic value falls but likely remains above $55. FCF growth of 2% (anchored to revenue CAGR of 0.37%) is actually conservative — management guided $450M FCF for 2026 vs. $422.7M base used, so the model isn't baking in heroic assumptions. ROIC of 4.74% vs. WACC of 7.0% is the most serious concern: at current ROIC, incremental growth is value-destructive, meaning the Gordon Growth terminal model overstates value by assuming profitable perpetual reinvestment. If ROIC stays below WACC, terminal value math breaks. However, the current ROIC likely understates normalized profitability — heavy goodwill from the Vayner acquisition ($3.7B long-term debt, $9.4B total assets) depresses the ratio, and operating ROIC on legacy business is probably higher. CapEx of $307M vs. OCF of $729M produces FCF yield of 9.2% at current price — that's a compelling real yield for a stable business. Price-to-FCF of 11.56x is cheap for a business with long-term contracted revenue (~90% of metal containers under 5–10 year contracts) and an 89-quarter dividend streak. The implied expectations at $46.23 are quite modest: roughly 2% perpetual FCF growth with no margin expansion — the reverse-engineered expectation the market is pricing in is essentially 'no improvement ever,' which is a low bar given management's guidance of $450M FCF in 2026 and dispensing segment organic growth inflecting. The terminal value represents 80.5% of intrinsic value — elevated but not unusual for a stable cash-flow business; still, sensitivity to terminal growth matters enormously. Revenue CAGR of 0.37% used as growth proxy is probably too conservative as a standalone assumption but is acceptable as a floor for the explicit period given current volume softness. Operating margin of 5.54% is thin but FCF conversion is solid (FCF margin 6.52%), suggesting D&A and working capital dynamics are favorable. Debt-to-equity of 1.63x and $3.7B long-term debt are material risks — any prolonged FCF shortfall or rate spike pressures the balance sheet. Net debt of $2.63B reduces equity value meaningfully in the DCF. On balance: the price is below a conservative intrinsic value even under a stress scenario, the implied expectations are modest and achievable, and the FCF yield is attractive. The ROIC-below-WACC issue is real and prevents a higher score, as is the terminal growth rate being at the upper end of defensible. This is a 'pass' with medium confidence — not a screaming bargain, but genuinely cheap on a story-to-numbers basis.

Key points

DCF intrinsic value $64.31/share vs. $46.23 price = 39% upside; bear-case $48.10 still above current price, providing meaningful margin of safety
FCF yield of 9.2% at current price ($422.7M FCF on $4.89B market cap) is attractive for a business with ~90% contracted metal container volumes and 89-quarter dividend streak
Management-guided $450M FCF for 2026 is 6.4% above the $422.7M base used in DCF — conservative modeling, not heroic assumptions
Implied market expectations at $46.23 are essentially 'no growth, no margin improvement' — a low bar given dispensing segment recovery and pet food capacity investments planned
WACC of 7.0% is defensible given beta 0.71 and stable contracted revenue base; not torturing the discount rate to make the math work
P/FCF of 11.56x and P/S of 0.75x are consistent with a deep-value packaging business, not momentum pricing

Red flags

ROIC of 4.74% is materially below WACC of 7.0% — at current returns, incremental reinvestment destroys value; Gordon Growth terminal value math overstates intrinsic value if this spread persists
Terminal growth of 2.5% sits at or above nominal GDP in a 4%+ risk-free rate environment — trimming to 2.0% is more defensible and reduces intrinsic value by ~$8–10/share
Terminal value represents 80.5% of enterprise value — extreme sensitivity to terminal growth assumption; a 50bp change in terminal growth moves value by ~15%
$3.7B long-term debt and net debt of $2.63B consume substantial equity value in the DCF; any FCF miss or rate shock could pressure covenant ratios
Revenue CAGR of 0.37% over 3 years is near-flat — if used as long-run growth anchor rather than a cyclical trough, it understates the reinvestment needed to generate even modest growth
Operating income period shown as 2019 in fundamentals data — possible data integrity issue; 2025 operating margin of 5.54% cannot be independently confirmed from the filings provided

Bruce Greenwald — 🟢 pass · 72/100 · medium confidence

Silgan Holdings is well-suited to EPV analysis: it has a long operating history, relatively stable normalized earnings, and operates in a capital-intensive packaging business where asset reproduction value can be estimated. My assessment centers on three Greenwald pillars: (1) EPV vs. market price, (2) EPV vs. asset reproduction value (moat test), and (3) margin of safety.

EPV Calculation: I normalize operating earnings by using reported net income of $288M (FY2025) and cross-checking against FCF of $423M. Operating income is oddly reported as $359M for the 2019 period in the fact base — this appears to be a data anomaly; I use the implied operating income from the 10-K period 2025 context instead. Net margin of 4.45% on $6.48B revenue yields ~$288M net income. ROIC is reported at 4.74%, which is barely above the 7% WACC used in the DCF — a signal that normalized earnings power, capitalized at WACC, will be close to or below enterprise value. Using adjusted distributable earnings closer to FCF ($423M), taxed and maintenance-capex-adjusted: FCF of $423M capitalized at 7% WACC implies an EPV of ~$6.0B enterprise value. Subtracting net debt of $2.63B yields equity EPV of ~$3.37B, or ~$32/share. This is BELOW the current price of $46.23, which is a yellow flag. However, FCF includes growth capex; maintenance capex is likely lower. Capex is $307M vs. D&A (not directly provided, but implied to be higher given capital intensity). If maintenance capex is ~60% of total capex (~$184M), distributable earnings rise to ~$546M, yielding EPV equity of ~$45-47/share — roughly in line with current price. This is a narrow margin of safety at best.

Asset Reproduction Value: Total assets of $9.4B, with goodwill/intangibles likely substantial given M&A history (Vayner acquisition in 2024). Tangible reproduction cost is probably $5-6B for physical plant and working capital. Adding the cost of rebuilding customer relationships (long-term contracts with blue-chip customers), the Silgan brand in metal containers, and the Vayner dispensing capability, reproduction value is perhaps $7-8B enterprise value — roughly $42-50/share equity. EPV appears roughly in line with reproduction value, suggesting a modest or no meaningful moat.

Moat Assessment: The packaging sector is competitive, but Silgan has genuine, if narrow, moat elements: (a) long-term contracts (~90% of metal container volume locked 5-10 years) providing customer captivity; (b) scale economies in regional metal can manufacturing (fixed-cost leverage); (c) dispensing/closures technology and switching costs in specialty segments. However, ROIC of 4.74% is not impressive and barely covers cost of capital, which is the ultimate moat test — weak evidence of durable excess returns. The dispensing segment (fragrance, pharma closures) has better economics, but Vayner integration opacity makes it hard to isolate.

DCF Sanity Check: The provided DCF yields $64.31/share intrinsic value with 39% upside, but it relies on a 2.5% terminal growth rate and an 80.5% residual terminal value weight — exactly the kind of far-future speculation I distrust. With ROIC barely at WACC, growth adds little EPV value and the DCF is likely overstating intrinsic value.

Margin of Safety: At $46.23, the stock appears roughly at or slightly below a conservative EPV that assumes some maintenance/growth capex split favorably. The bear DCF scenario of $48.10 is only modestly above current price. The 89-quarter dividend streak, ~$450M FCF guidance for 2026, and Q1 2026 beat are positive signals, but the margin of safety under strict EPV is thin — perhaps 0-15%. The P/FCF of 11.6x and P/S of 0.75x are value-friendly, but leverage (D/E 1.63, net debt $2.63B) reduces equity cushion. I give a cautious 'pass' rather than 'watch' because the capital-light FCF yield, long-term contracts, and deleveraging trajectory provide a real if modest margin of safety for a patient value investor, and the dispensing franchise has genuine switching-cost moat characteristics that could support EPV above my conservative base case.

Key points

EPV on a maintenance-capex-adjusted FCF basis (~$546M distributable earnings / 7% WACC) yields equity value of ~$45-50/share, roughly in line with the current $46.23 price — thin but real margin of safety
Asset reproduction value estimated at $7-8B enterprise value; EPV roughly matches, suggesting a narrow/modest competitive advantage rather than a deep franchise — growth adds limited value in this framework
Long-term contracts covering ~90% of metal container volume and switching costs in dispensing/closures (fragrance, pharma) provide genuine, if narrow, customer captivity — the core of any moat case
ROIC of 4.74% barely covers 7% WACC, the most important moat indicator — suggests competitive, not franchise-grade, returns on the consolidated business
P/FCF of 11.6x and P/S of 0.75x screen as value-friendly; $450M FCF guidance for 2026 and deleveraging trajectory improve forward EPV
The provided DCF ($64/share, 80% terminal value weight) is precisely the kind of growth-dependent, long-horizon estimate I distrust — not the anchor for this analysis
89-quarter dividend streak and Q1 2026 beat provide operational confidence; management capital allocation (buybacks at lows, systematic deleveraging) is consistent with value-oriented stewardship

Red flags

ROIC of 4.74% barely covers cost of capital — thin evidence of durable moat; returns at risk of mean-reversion in a competitive packaging market
Net debt of $2.63B (D/E 1.63) limits equity margin of safety and amplifies earnings volatility risk if consumer bifurcation persists in DSC segment
DCF terminal value is 80% of total value — exactly the speculative far-future dependence that EPV methodology rejects; DCF should not be used as primary anchor
Late-cycle demand miss in Q3/Q4 2025 (DSC volume shortfall discovered in late September) raises forward visibility concerns; management's ability to forecast organic volumes in dispensing segment is in question
Vayner acquisition P&L opacity post-integration makes it impossible to isolate organic EPV from inorganic contribution — serial M&A blurs true sustainable earnings
Revenue CAGR of only 0.37% over 3 years confirms this is a slow-growth, essentially GDP-or-below business — growth value is minimal under EPV framework, but also means DCF growth assumptions of 2% are not clearly supported

Forensic Short-Seller (Chanos/Einhorn-style) — 🟢 pass · 62/100 · medium confidence

Silgan Holdings is a capital-intensive serial acquirer (Vayner, multiple prior roll-ups) in packaging, which warrants a thorough forensic look. However, the accounting quality holds up better than feared. Operating cash flow ($729.8M) substantially exceeds net income ($288.4M), which is a strong positive signal — earnings are turning into cash and then some. FCF of $422.7M vs. net income of $288.4M means free cash flow EXCEEDS reported earnings, the opposite of the classic Chanos red flag. ROIC at 4.7% is below WACC of 7%, suggesting value destruction at the margin, but this is a business quality issue, not an accounting fraud signal. The principal concerns are: (1) elevated leverage ($3.72B long-term debt, D/E of 1.63x) post-Vayner acquisition with net debt of ~$2.63B vs. FCF of ~$423M implying ~6.2x net debt/FCF — manageable but not comfortable; (2) operating margin of only 5.5% with limited buffer for earnings miss; (3) management's late visibility into Q4 2025 DSC weakness (discovered only late September) raises questions about internal forecasting and customer intelligence; (4) the PEG of 45.78 on 0.37% revenue CAGR is alarming — growth is essentially flat, yet the stock isn't priced as a no-growth utility; (5) the operating income figure cited ($359M for 2019 period) appears to be a data artifact — the fact base shows operating_income_period as 2019-12-31 while revenue is 2025, suggesting possible data misalignment. The non-GAAP adjusted EPS narrative ($3.72 in 2025 vs. GAAP net income implying ~$2.73/share) represents a meaningful gap (~36%) that warrants scrutiny of what is being excluded. The dividend streak (89 quarters) is maintained, but with $3.7B in long-term debt and near-flat revenue growth, the capital allocation story depends entirely on sustained FCF. The DCF intrinsic value ($64.31/share vs. $46.23 current) offers apparent upside, but the terminal value represents 80.5% of enterprise value — extremely sensitive to the 2.5% terminal growth assumption for a business with 0.37% revenue CAGR. The bear case is not a fraud thesis but rather: leverage + no growth + aggressive non-GAAP framing + late earnings visibility = value trap. The bull case (strong FCF, deleveraging path, dispensing segment growth) is credible enough that this is not a clean short.

Key points

OCF ($729.8M) massively exceeds net income ($288.4M) — FCF quality is genuinely good, the opposite of the classic earnings-inflation red flag
FCF ($422.7M) exceeds GAAP net income ($288.4M), meaning cash earnings are higher than reported earnings — forensically clean
Adjusted EPS of $3.72 in 2025 vs. implied GAAP EPS of ~$2.73 (288.4M/105.4M shares) = ~36% non-GAAP inflation; recurring 'adjustments' deserve itemization
Net debt/FCF of ~6.2x is elevated post-Vayner; $3.72B LTD with only 5.5% operating margin creates limited covenant headroom if FCF compresses
Revenue CAGR of 0.37% over 3 years with a PEG of 45.78 signals a no-growth business priced with modest growth expectations — value trap risk
Terminal value = 80.5% of DCF enterprise value using 2.5% terminal growth vs. 0.37% revenue CAGR — valuation highly sensitive to long-run assumption
Operating income period flagged as 2019 in the fact base while other metrics are 2025 — potential data artifact warrants verification
Late Q4 2025 DSC demand discovery (early October vs. late September events) suggests weak real-time customer intelligence or information management lag

Red flags

Non-GAAP adjusted EPS ($3.72) materially exceeds implied GAAP EPS (~$2.73) — ~$1/share in recurring 'adjustments' needs itemization to assess quality
Net leverage of ~6.2x FCF is concerning for a capital-intensive business with near-flat revenue growth; any FCF compression tightens the debt service math
Revenue growth essentially flat (0.37% CAGR) while management guides 'continued growth' — narrative vs. reality gap
Management acknowledged mid-single-digit DSC organic growth guidance for 2026 is below historical rates and below initial Vayner acquisition thesis — integration risk crystallizing
One large metal container customer filed for bankruptcy mid-Q3 2025 — customer concentration risk in what management describes as 'blue-chip' book
Terminal value dependency (80.5%) means the DCF bull case is almost entirely a long-run growth bet on a company with demonstrably sub-2% revenue growth
Operating income data point appears to reference FY2019, not FY2025 — if operating leverage has structurally declined, the FCF story may be less durable than headline numbers suggest

Joel Greenblatt — 🟡 watch · 58/100 · medium confidence

Silgan is a legitimate operating business with measurable EBIT and tangible capital — exactly the kind of company where the Magic Formula framework applies. However, applying Greenblatt's dual-axis test reveals a mixed picture. On earnings yield (EBIT/EV): operating income reported is $359M (noted as 2019 period in the fact base — a data anomaly I flag), but using a more reliable proxy from FCF and net income, normalized EBIT is closer to ~$450-500M. Enterprise Value = market cap ($4.89B) + long-term debt ($3.72B) - excess cash (~$1.08B) ≈ $7.53B. This gives an EBIT/EV earnings yield of roughly 6-7%, which is decent but not exceptional — not the 10%+ Greenblatt would call a screaming buy. On ROIC (EBIT / net working capital + net fixed assets): working capital is thin (current assets $2.99B - current liabilities $2.45B = $540M net), but fixed assets are not directly broken out from the filing excerpts. Using total assets ($9.4B) minus intangibles/goodwill (significant given Vayner and prior acquisitions) is rough; the reported ROIC of 4.74% is well below a Greenblatt-quality threshold of 15%+. The debt load is substantial at $3.72B long-term debt vs. $2.27B equity (D/E 1.63x), which inflates EV and suppresses the earnings yield below what the P/E of ~17x might superficially suggest. Free cash flow is real and strong ($423M in 2025, guided $450M in 2026), and the business does have genuine economics — long-term contracts, blue-chip customers, 90% of metal container volume under 5-10 year agreements. But the Magic Formula requires BOTH high ROIC and high earnings yield simultaneously. SLGN fails to clearly score well on ROIC (packaging is capital-intensive with modest returns on tangible assets), and the earnings yield is moderate rather than exceptional given the leverage-inflated EV. The revenue CAGR of 0.37% over 3 years confirms this is a low-growth, capital-intensive business earning modest returns — not the kind of above-average business Greenblatt prefers to pair with cheapness. No special-situation catalyst is present (Vayner integration is largely complete; no spinoff, restructuring, or recapitalization). The DCF intrinsic value of $64.31 vs. current price of $46.23 (39% upside) is interesting but relies heavily on terminal value (80.5% of EV), making it sensitive to growth and WACC assumptions. A watch rather than pass: the stock is not expensive, but it doesn't rank highly on the combined Magic Formula axes that define a Greenblatt buy.

Key points

Earnings yield (EBIT/EV) estimated at ~6-7% using normalized EBIT ~$450-500M against EV ~$7.5B — decent but below the 10%+ Greenblatt threshold for a clear buy
Reported ROIC of 4.74% is materially below the 15%+ that characterizes a high-quality Magic Formula business; packaging is capital-intensive with modest tangible returns
Free cash flow is real and repeatable ($423M 2025, $450M guided 2026) — owner economics are genuine, not accounting fiction
Long-term customer contracts (~90% of metal container volume, 5-10 year agreements with investment-grade counterparties) provide earnings quality and visibility
Debt load of $3.72B long-term inflates EV significantly, suppressing earnings yield and making the business less cheap than the P/E of ~17x alone implies
No special-situation catalyst present — Vayner integration mostly complete, no spinoff/restructuring/recap to create forced-selling mispricing
DCF shows 39% upside to $64.31 intrinsic value, but 80.5% terminal value dependency makes this sensitive to long-run assumptions
Q1 2026 beat and raised guidance ($3.73-$3.93 EPS, $450M FCF) signal operational momentum recovery from 2025 weakness

Red flags

ROIC of 4.74% falls far short of Greenblatt's quality threshold — the business does not earn exceptional returns on tangible capital employed
Operating income figure cited as 2019 period ($359M) creates data reliability concern for precise EBIT/EV calculation; normalized EBIT must be estimated
Leverage (D/E 1.63x, $3.72B LTD) makes EV cheapness illusory — a 'cheap' P/E masks an expensive enterprise-value picture
Revenue CAGR of only 0.37% over 3 years confirms low-growth, commodity-like economics inconsistent with a high-ROIC Magic Formula business
No identifiable special-situation catalyst to close any discount on a defined timeline
Consumer bifurcation risk in DSC segment (personal care/home care weakness among lower-income consumers) creates near-term earnings volatility that could deteriorate already-modest EBIT/EV

Howard Marks — 🟡 watch · 58/100 · medium confidence

SLGN presents a genuinely mixed picture through the Marks lens. On the positive side, the price appears demonstrably below conservative intrinsic value — the DCF yields $64.31/share vs. $46.23 current price (39% upside), and even the bear case of $48.10 sits above today's price. The P/FCF of 11.6x on $423M of actual free cash flow is undemanding for a packaging business with mostly captive, long-term contracted volumes. The 89-quarter dividend streak and $450M guided FCF for 2026 suggest real cash generation, not accounting fiction. Sentiment is muted — one disgruntled retail holder calls management overpaid, options traders are picking up small call positions, and institutional coverage is tepid. This is not a name priced for perfection. The stock trades 19% below its 52-week high ($57.04), having been beaten down from DSC weakness and a Q4 2025 guidance cut — classic fear-driven price action that can create opportunity. HOWEVER, the balance sheet is a meaningful concern from a Marks risk perspective. Net debt of $2.63B against FCF of $423M implies ~6x net debt/FCF — elevated, particularly post-Vayner acquisition. Long-term debt of $3.72B against stockholders' equity of $2.27B gives a D/E of 1.63x, and total assets of $9.4B include substantial goodwill/intangibles from the acquisition-heavy growth model. ROIC of only 4.7% barely covers the 7% WACC — this is a capital-heavy, thin-margin business where the returns on deployed capital are structurally modest. Operating margin of 5.5% leaves little cushion for revenue disappointment. The DCF is heavily back-end loaded (80% terminal value) and uses a 2% near-term FCF growth rate that is basically flat-real — defensible but not conservative enough given the consumer bifurcation uncertainty. The margin of safety exists but is not wide enough given the leverage profile. The low-bar case (bear DCF $48.10) barely covers current price, meaning a slightly worse revenue outcome or higher interest rates eliminate the cushion. Second-level thinking: consensus sees SLGN as a boring, defensive packaging play with modest yield — this view is broadly correct but the leverage and execution risk in DSC integration are under-appreciated. The variant view that this is cheap because of transient consumer weakness has merit, but it is not a deeply contrarian call — it is the obvious bull thesis, well-articulated by management and sell-side. The real edge would require high conviction that DSC organic growth re-accelerates and deleveraging proceeds as planned — that is a lot to bank on in a cycle-uncertain environment. In sum: some margin of safety exists, sentiment is subdued, and FCF is real. But leverage is uncomfortably high for a Marks-style risk-first framework, ROIC barely covers cost of capital, and the variant view is not truly contrarian — it is the consensus bull case. A watch, not a pass, until leverage falls materially closer to 4x or the price drops another 10-15% to widen the safety cushion.

Key points

DCF intrinsic value $64.31 vs. $46.23 price represents ~39% upside with bear case ($48.10) only marginally above current price — partial but not wide margin of safety
P/FCF of 11.6x on $423M real FCF is undemanding; $450M 2026 FCF guidance confirmed post-Q1 beat suggests durable cash generation
89-quarter dividend streak and long-term contracts (~90% of metal container volumes with investment-grade counterparties) provide income floor and cash flow predictability
Sentiment subdued — stock 19% off 52-week high, retail commentary disappointed, institutional consensus tepid — pendulum has swung toward mild fear, not panic
Q1 2026 beat and raised guidance ($3.73-$3.93 adj EPS) signals the Q4 2025 weakness may have been transient, not structural — lowers probability of permanent impairment
Low beta (0.71) and steady FCF through consumer cycle suggests limited equity volatility risk, though credit risk from leverage is the real exposure

Red flags

Net debt ~$2.63B implies ~6x net debt/FCF — elevated for a thin-margin packaging business, especially post-acquisition; leverage must decline materially before balance sheet risk is comfortable
ROIC of 4.7% barely covers 7% WACC — returns on capital are structurally modest, limiting intrinsic value creation and the quality of the 'moat'
Operating margin of only 5.5% provides minimal buffer against volume or pricing deterioration; a modest revenue miss could compress FCF significantly
DCF terminal value represents 80% of enterprise value — intrinsic value is extremely sensitive to terminal growth assumptions and is not 'on the asset' coverage
DSC demand visibility admitted to be poor (late-Sept forecast only available early Oct) — execution risk in the highest-margin segment is not fully priced in
Bull thesis (transient consumer bifurcation, DSC re-acceleration, smooth deleveraging) is the consensus first-level view — no true variant edge or contrarian setup visible

Ray Dalio — 🟡 watch · 55/100 · medium confidence

Silgan Holdings is a leveraged industrial packaging company with genuinely non-cyclical end markets (food/beverage, pet food, personal care, pharma closures) that provide meaningful regime resilience — but the balance sheet carries notable debt load (~$3.7B long-term debt, net debt ~$2.6B) post-Vayner acquisition. From a Dalio regime lens, SLGN exhibits mixed characteristics: its core metal container and dispensing closure revenues are tied to non-discretionary consumer staples demand, offering some insulation across growth/inflation regimes, but the leverage and refinancing exposure create fragility in a sustained higher-rate or deflationary deleveraging scenario. The DCF implies ~39% upside to intrinsic value (~$64/share base case) at a 7% WACC, suggesting modest margin of safety — but this is heavily terminal-value dependent (80% of EV from TV), making it sensitive to rate and growth assumptions. Revenue CAGR of only ~0.4% over 3 years with 5.5% operating margins reflects a commoditized, volume-driven business with limited organic growth, though FCF conversion is strong ($423M FCF on $6.5B revenue, FCF yield ~8.6% on market cap). The 2% FCF growth assumption in the DCF is plausible but arguably optimistic given the historical revenue stagnation. Key concerns: debt/equity of 1.63x, ROIC of 4.7% barely covering likely WACC, and management's admitted late-cycle visibility problems in DSC suggest information asymmetry risk. On the positive side: long-term contracts (~90% metal containers), blue-chip investment-grade customer base, low beta (0.71), 89-quarter dividend streak, and ~$450M FCF guidance for 2026 indicate through-cycle durability. Geographic diversification appears limited (primarily North American), adding concentration risk in a world-order-shift scenario. The operating margin of 5.5% is thin and would compress materially in a stagflationary environment if pass-through mechanisms lag, though long-term contracts with cost pass-through features partially mitigate this.

Key points

Non-discretionary end markets (food, pet food, pharma closures) provide regime robustness — demand holds up in stagflation and deflationary bust unlike discretionary cyclicals
FCF generation is genuine and durable: $423M trailing FCF, $450M guided 2026, yielding ~8.6% on market cap — strong self-funding capacity
Low beta (0.71) and non-correlated return drivers (packaging volumes vs. GDP growth) add diversification value to a typical equity book
Long-term contracts (~90% metal container volumes, 5-10 year terms) with pass-through mechanisms provide inflation protection and revenue visibility
DCF base case of $64.31/share implies ~39% upside at conservative 2% FCF growth — asymmetric if deleveraging proceeds as guided (~$450M annual FCF can retire net debt meaningfully)
89-quarter dividend streak signals management commitment to capital return even through downturns — behavioral signal of balance-sheet confidence
Q1 2026 beat and raised guidance ($3.73-$3.93 EPS) suggests 2025 DSC headwinds are transient, not structural

Red flags

High leverage: $3.7B long-term debt, net debt ~$2.6B, D/E ratio 1.63x — elevated post-Vayner acquisition and creates refinancing exposure in higher-for-longer rate environment
ROIC of 4.7% barely clears the 7% WACC used in DCF — value creation is marginal and any rate increase erodes the spread entirely
DCF terminal value represents 80% of enterprise value — extremely sensitive to terminal growth and WACC assumptions; a 100bp WACC increase would materially impair the intrinsic value
Revenue CAGR of only 0.37% over 3 years reflects near-zero organic growth — the business is capital-intensive with thin margins (5.5% operating, 4.5% net) and limited pricing power beyond cost pass-through
Geographic concentration: primarily North American revenues create vulnerability to a weaker USD purchasing power cycle or US-specific demand contraction
Consumer bifurcation in DSC segment (personal care/home care weakness among lower-income consumers) creates downside risk if consumer stress deepens — late-Q 2025 visibility failure raised forecasting credibility concerns
Operating margin of 5.5% is thin and could compress in stagflation if input cost pass-through lags contractual cycles — steel/aluminum exposure without perfect real-time hedging
Debt maturity profile details not fully visible in the fact base — refinancing risk in higher-rate environment cannot be fully assessed from available filings

Benjamin Graham — 🟡 watch · 55/100 · medium confidence

Silgan Holdings presents a mixed Graham scorecard. On the positive side, the company has demonstrated earnings durability (profitable, established industrial packaging business), an uninterrupted dividend streak of 89 consecutive quarters, a modest trailing P/E of ~16.9x (near but slightly above Graham's 15x defensive ceiling), a very low price-to-sales of 0.75x, and a price-to-FCF of just 11.6x which is genuinely cheap. The DCF intrinsic value of $64.31/share implies ~39% upside from the current $46.23, which if credible would represent a meaningful margin of safety. The Q1 2026 beat and raised guidance, combined with confirmed $450M FCF target, support earnings durability. However, the balance sheet is where Silgan fails Graham's conservative standards most decisively. Long-term debt of $3.715B dwarfs net working capital (current assets $2.992B minus current liabilities $2.452B = working capital of only ~$540M), violating the core Graham rule that long-term debt should not exceed net current assets — here it exceeds by nearly 7x. The current ratio of 1.22 falls well short of Graham's minimum of 2.0. The debt-to-equity of 1.63 is elevated. The P/B of 2.15 combined with the P/E of 16.94 yields a P/E x P/B product of ~36.4, nearly double Graham's 22.5 ceiling. This is emphatically not a net-net situation — the stock is far above net current asset value per share (NCAV = current assets minus ALL liabilities: $2.992B - $2.452B current - $3.715B LT debt = deeply negative). ROIC of only 4.74% barely clears the cost of capital. Revenue CAGR of only 0.37% over 3 years signals stagnation. The consumer bifurcation headwinds in personal care/home care, late-cycle demand visibility issues flagged in Q3 2025, and the Q4 2025 guidance cut all raise earnings stability questions. Leverage incurred from the Vayner acquisition adds financial risk. The stock trades at its 52-week high, meaning Mr. Market is currently optimistic, not pessimistic — hardly the bargain-basement purchase Graham preferred. In sum: a real, profitable industrial business with dividend continuity and some valuation appeal on earnings/FCF, but the balance sheet fails Graham's conservative standards materially, multiples slightly exceed defensive thresholds, and leverage is a genuine risk to capital preservation.

Key points

89-quarter uninterrupted dividend streak satisfies Graham's dividend reliability criterion
Trailing P/E of 16.9x is only modestly above Graham's 15x defensive ceiling; price-to-FCF of 11.6x is genuinely inexpensive
DCF intrinsic value of $64.31 implies ~39% upside, which approaches but does not fully achieve Graham's preferred one-third discount
Price-to-sales of 0.75x is low, suggesting market is not pricing in rosy growth expectations on revenue
Established, large-cap industrial packaging business with long-term contracts (~90% of metal container volume) and blue-chip customers satisfies Graham's adequacy-of-size test
Q1 2026 earnings beat with raised full-year guidance confirms near-term earnings momentum

Red flags

Long-term debt of $3.715B exceeds working capital of ~$540M by nearly 7x — a decisive violation of Graham's core balance-sheet test
Current ratio of 1.22 falls far short of Graham's minimum 2.0 threshold
Net current asset value (NCAV) is deeply negative after deducting all liabilities from current assets — not remotely a net-net
P/E x P/B product of ~36.4 nearly doubles Graham's 22.5 ceiling, indicating the stock is not cheap on a combined earnings-and-asset basis
Revenue CAGR of only 0.37% over three years signals stagnation; no meaningful per-share earnings growth demonstrated in the data provided
Stock is trading at its 52-week high ($46.23 = 52-week high), meaning Mr. Market is optimistic, not offering a bargain-hunter's entry point
ROIC of 4.74% is barely above the 7% WACC used in DCF, suggesting marginal capital allocation efficiency

Warren Buffett — 🟡 watch · 52/100 · medium confidence

Silgan Holdings is an understandable, established business — rigid metal containers, dispensing closures, custom containers — with a long operating history (decades), predictable end markets (food, pet food, personal care, pharma), and a meaningful FCF generation record. This sits within my circle of competence. However, it falls short on several of my most important criteria. The moat question is genuine but limited: Silgan has long-term customer contracts (~90% of metal container volume under 5–10 year agreements with investment-grade customers), which creates meaningful switching friction and revenue visibility, but this is not a brand or network-effect moat — it is a commodity-adjacent manufacturing business where pricing power is constrained by input costs (steel, resin) and where contract renegotiation every 5–10 years introduces episodic margin risk. ROIC of 4.7% is far below my 15% threshold and reflects the capital intensity of this business — $307M capex against $730M operating cash flow means maintenance and growth capex consumes a substantial portion of earnings. ROE of 12.7% is better but is flattered by $3.7B of long-term debt (D/E of 1.63×); strip out leverage and the underlying business returns are mediocre. Owner earnings: FCF of $422M on $6.5B revenue is respectable in absolute terms, and the DCF suggests ~39% upside to intrinsic value at $64.31/share vs. $46.23 price — a reasonable margin of safety IF you trust 2% perpetual FCF growth with a 7% WACC, which I consider aggressive given the near-zero 3-year revenue CAGR (0.37%). The Vayner acquisition added debt and integration complexity; management's late detection of DSC weakness (discovered only in late September 2025) raises questions about business visibility. The 89-quarter dividend streak and opportunistic buybacks below intrinsic value (Q1 2025, ~$60M at low prices) are positives on capital allocation. But the combination of leverage-inflated returns, thin organic growth, capital intensity, and a modest (not durable) competitive position keeps this in watch territory for me — not a wonderful business at a fair price, more a decent business at a fair price.

Key points

Long-term customer contracts (~90% metal container volume, 5–10 year terms, investment-grade customers) provide revenue visibility and switching-cost-like stickiness — a partial moat
FCF of $422M (2025) with $450M guided for 2026 is real and substantial; price-to-FCF of 11.6× is genuinely cheap on a cash basis
89-quarter consecutive dividend streak demonstrates long-term earnings durability and management commitment to shareholder returns
DCF intrinsic value of $64.31/share implies ~39% upside from $46.23, providing a meaningful margin of safety IF growth assumptions hold
Management buyback of ~$60M in Q1 2025 at depressed prices indicates rational capital allocation and insider conviction
Dispensing & Specialty Closures segment (fragrance, pharma) shows genuine differentiation with 15% organic growth in Q3 2025 high-end products — a potentially higher-quality sub-business within the portfolio

Red flags

ROIC of 4.7% is well below my 15% hurdle — the underlying business earns poor returns on the capital it deploys, a hallmark of a commodity manufacturer not a moat business
Long-term debt of $3.72B against stockholders equity of $2.27B (D/E 1.63×) means ROE of 12.7% is heavily leverage-assisted; unlevered returns are uninspiring
Revenue CAGR of only 0.37% over 3 years — essentially zero organic growth — makes the DCF's 2% perpetual FCF growth assumption optimistic and the terminal value (80.5% of total DCF value) fragile
Capital intensity is high: $307M capex vs. $422M FCF means capex consumes ~73% of operating cash flow; maintenance capex is difficult to isolate from growth capex, making true owner earnings uncertain
Late discovery of DSC volume weakness (September 2025, only known in early October) reveals limited forward visibility — a concerning characteristic for a business I need to forecast a decade out
Operating margin of only 5.5% leaves thin cushion; any input cost spike (steel, resin, energy) or volume shortfall compresses economics rapidly with limited pricing power offset
PEG ratio of 45.78 reflects the near-zero growth environment; growth is not being delivered to justify retention of capital beyond dividend

Seth Klarman — 🟡 watch · 52/100 · medium confidence

Silgan Holdings presents a moderately interesting value situation but falls short of the margin-of-safety bar I require before committing capital. The DCF intrinsic value of $64.31/share implies ~39% upside to the $46.23 current price, which is meaningful, and the price-to-FCF of 11.56x on $422M trailing FCF is genuinely undemanding for a steady industrial packaging business with long-term contracts. However, several features prevent a full 'pass.' First, the leverage is a serious concern: $3.72B in long-term debt against $2.27B in equity (D/E of 1.63x) and net debt of ~$2.63B means the balance sheet is not conservative. At 7% WACC with 80.5% of enterprise value sitting in a terminal value that assumes 2.5% perpetual growth, the intrinsic value is highly sensitive to terminal assumptions — the bear case of $48.10 barely clears the current price, offering negligible margin of safety in a stress scenario. Second, the DCF itself is built on 2% FCF growth anchored to a 3-year revenue CAGR of 0.37% — this is actually quite modest, but it means upside is entirely dependent on the terminal value holding, which is exactly the kind of optimism-dependent single-method valuation I distrust. Third, the operating margin is thin at 5.54% with ROIC of only 4.74% — barely above WACC — suggesting the business generates only marginal economic value after capital costs, undermining the moat thesis. Fourth, management disclosed late-cycle demand visibility problems in Q4 2025 (DSC headwind discovered in late September), raising governance/disclosure concerns. Fifth, capex of $307M versus $422M FCF means maintenance and growth capex are consuming 73% of operating cash flow, leaving true 'owner earnings' tighter than FCF suggests. On the positive side: 89 consecutive quarterly dividends, ~90% of metal container volumes under long-term blue-chip contracts, Q1 2026 beat with raised guidance to $3.73–$3.93 EPS and $450M FCF, low beta (0.71), and price-to-sales of 0.75x all suggest a business with defensive characteristics. The Seeking Alpha note that strong cash flows will reduce net debt quickly is credible but requires sustained FCF delivery. The $36–$37 technical support level identified by retail participants aligns with the area where downside risk becomes more asymmetric — roughly 20–22% below current price — which is where I would grow genuinely interested. At $46, risk-reward is mixed but not compelling enough for a conviction position given leverage and thin margins of safety in the bear case.

Key points

DCF intrinsic value $64.31 vs. $46.23 current price implies ~39% upside, meaningful but not a deep enough discount given balance sheet risk
Price-to-FCF of 11.56x and P/S of 0.75x are undemanding multiples for a defensive packaging business
~90% of metal container volumes under long-term 5–10 year contracts with investment-grade blue-chip customers provides real earnings floor
89-quarter consecutive dividend streak demonstrates capital discipline and earnings durability
Q1 2026 beat and raised FY2026 EPS guidance to $3.73–$3.93 with $450M FCF confirmation signals recovery momentum
Low beta (0.71) and consumer staples-adjacent revenue mix (food cans, pet food, healthcare dispensing) provide defensive characteristics

Red flags

Net debt of ~$2.63B versus $422M trailing FCF means ~6.2x FCF leverage — dangerous if volumes decline further or interest rates rise
80.5% of DCF enterprise value rests in terminal value, making intrinsic value highly sensitive to growth and WACC assumptions — bear case $48.10 barely clears current price
ROIC of 4.74% barely exceeds WACC of 7% — marginal economic value creation undermines the moat and questions capital allocation quality
Capex of $307M consumes 73% of operating cash flow, true owner earnings are materially tighter than reported FCF
Management acknowledged late-cycle DSC demand visibility failure in Q4 2025 — discovered $25M headwind only in late September — raising disclosure and forecasting quality concerns
Operating margin of 5.54% is thin; any commodity cost pressure, volume shortfall, or interest expense increase materially compresses earnings
DCF residual value 80.5% in terminal — thesis is not asset-backed or catalyst-driven, purely a going-concern growth story dressed as value

Peter Lynch — 🟡 watch · 52/100 · medium confidence

Silgan is a classic stalwart-to-slow-grower packaging company — understandable business (metal cans, dispensing closures, custom containers for consumer staples), visible products in everyday life, and a durable 89-quarter dividend streak. But the Lynch PEG framework is deeply problematic here. The reported PEG of 45.78 is catastrophically high — even if that reflects a one-year anomaly in EPS growth, the 3-year revenue CAGR is only 0.37%, which is essentially zero. At a P/E of ~17x with near-zero organic earnings growth, there is no PEG safety margin. Even accepting management's forward guidance of $3.73–$3.93 adjusted EPS for 2026 (roughly 2% growth at midpoint from $3.72 in 2025), the yield-adjusted PEG using a ~2% dividend yield and ~2% EPS growth still implies a PEG near 2.8 — well above my 1.0 threshold. That said, there are real Lynch-style positives: the dispensing/closures segment has a genuine roll-out story (fragrance, pharma, beauty growing 15-40% organically in Q3 2025), the Vayner acquisition looks strategically sound rather than diworsification, metal container contracts are 5-10 years with blue-chip customers (Heinz, pet food brands), and Q1 2026 beat with raised guidance suggests the 2025 consumer bifurcation headwinds may be transient. FCF of $422M against a $4.9B market cap gives a price-to-FCF of ~11.6x, which is genuinely cheap. The DCF intrinsic value of $64.31/share implies 39% upside and the bear case of $48.10 is essentially the current price — limited downside on DCF. However, the balance sheet is a Lynch red flag: $3.7B long-term debt, D/E of 1.63, and net debt of $2.6B. For a slow-growing industrial, this is uncomfortable leverage. Leverage is post-Vayner and management targets deleveraging, but any demand miss extends the timeline. The dispensing segment's organic growth story (the only genuine fast-grower characteristic here) lacks visibility after consumer bifurcation, and management itself guided conservatively. This is not a neglected name — RBC Capital raised its target post-Q1 beat, Truist has a Buy at $63, and the stock trades at a 52-week high at time of this report. The 'neglected stalwart' discount has partially closed. Category is stalwart/slow-grower with one fast-growing sub-segment; the valuation is fair-to-cheap for a stalwart but the growth rate doesn't justify excitement.

Key points

Stalwart/slow-grower classification: packaging company serving consumer staples with ~0% organic revenue CAGR over 3 years — Lynch would buy stalwarts only at 30-50% gains and sell when P/E reaches full value
Dispensing & Specialty Closures is the fast-grower within: 40% dispensing product growth in Q3 2025, record EBIT, double-digit fragrance/beauty organic growth — a genuine sub-segment roll-out story Lynch would find exciting
FCF of $422M with $450M guided for 2026 at price-to-FCF of ~11.6x is genuinely cheap for a consistent cash generator; DCF supports $64 intrinsic value with 39% upside
89-quarter unbroken dividend streak signals financial discipline; management returned >$120M via dividends and buybacks in 9 months of 2025, including ~$60M buyback when stock was seen as undervalued
Metal container contracts are 5-10 years with blue-chip investment-grade customers (~90% covered); pet food 10% growth adds a durable sub-segment growth driver
Q1 2026 beat and raised full-year guidance ($3.73-$3.93) signals 2025 headwinds were transient, consistent with the Lynch turnaround-within-stalwart thesis

Red flags

PEG of 45.78 reported; even using forward 2% EPS growth with dividend yield, yield-adjusted PEG remains near 2.5-3.0 — far above Lynch's 1.0 comfort threshold
Leverage is a serious Lynch red flag: $3.7B long-term debt, D/E of 1.63, net debt $2.6B — Lynch avoids heavy bank debt especially in slow-growing industrials
Revenue CAGR of only 0.37% over 3 years confirms slow-grower/stalwart status — no Lynch fast-grower premium is warranted at current multiples
Consumer bifurcation uncertainty: management cannot quantify recovery timeline for personal care/home care weakness in DSC segment; late-cycle discovery of Q4 weakness (early October) raises forecasting credibility concerns
Stock is at 52-week high per price data (last close = 52-week high of $46.23), analyst coverage growing (RBC raised target), Truist at $63 Buy — the neglected-stock discount that Lynch prizes is gone
Vayner integration opacity: management cannot isolate Vayner P&L post-integration, making it hard to assess organic vs. inorganic growth in the highest-value segment

Charlie Munger — 🟡 watch · 52/100 · medium confidence

Silgan is an understandable, long-operating business in rigid packaging — metal cans, dispensing/specialty closures, and custom containers — serving consumer staples and household products. The business model is legible: long-term contracts, blue-chip customers, modest capital intensity relative to cash generation. However, applying the Munger quality lens reveals a company that is decent but not great. ROIC of 4.7% is far below the 15%+ threshold I require for a genuinely high-quality compounder; this is a capital-heavy, low-margin packaging business (operating margin ~5.5%, net margin ~4.5%) that earns returns barely above its cost of capital. The moat is real but narrow — long-term contracts (5-10 years) and switching costs provide stability, not pricing power. Gross margins and returns have not demonstrated the sustained excellence I associate with durable moats. The balance sheet carries significant leverage: $3.7B long-term debt against $2.3B equity, debt-to-equity of 1.63, and net debt of ~$2.6B versus ~$423M FCF, implying roughly 6x net debt/FCF — this is fragile and leaves little room for error. The Vayner acquisition added debt and integration opacity. Management has been largely candid (89-quarter dividend streak, transparent Q3 miss explanation) and capital allocation is reasonable but not exceptional. The DCF suggests ~39% upside to intrinsic value ($64 vs. $46), and the price-to-FCF of 11.6x is genuinely cheap, but cheapness alone is a cigar-butt argument, not a quality argument. The PEG of 45.8x (revenue CAGR of 0.37% applied against earnings) signals minimal organic growth runway. FCF of $422-450M is strong and real cash, which is a positive quality signal, and the company confirmed $450M FCF guidance for 2026. But high FCF relative to net income partially reflects low reinvestment returns — the business spits out cash because it lacks high-return reinvestment opportunities. Consumer bifurcation in dispensing/closures adds near-term uncertainty. I do not see the hallmarks of a Munger-quality compounder: sustained high ROIC, clear pricing power widening margins, or a business that can compound intrinsic value per share at 15%+ for a decade. At a cheaper price or with a cleaner balance sheet this would be more interesting; as it stands, it is a watchlist 'fair business at a fair price' — not the 'wonderful business at a fair price' I insist upon.

Key points

Understandable business model: long-term contracts with investment-grade customers in metal cans and dispensing closures — easily fits circle of competence
FCF generation is genuine and strong ($423M-$450M), backed by real cash; price-to-FCF of 11.6x is statistically cheap
89-quarter dividend streak signals management commitment to shareholder returns and financial discipline
DCF intrinsic value ~$64 vs. $46 price implies a real margin of safety on a DCF basis — not overpriced
Dispensing/specialty closures (post-Vayner) provide a higher-quality growth vector with double-digit organic growth in fragrance/beauty/healthcare
Long-term contracts (~90% of metal container volumes) reduce demand volatility and provide earnings predictability

Red flags

ROIC of 4.7% is deeply sub-par for a Munger-quality business — returns barely exceed cost of capital, indicating weak competitive moat economics
Leverage is high and concerning: $3.7B long-term debt, ~6x net debt/FCF — a temporary earnings miss or recession could become a permanent capital impairment event
Revenue CAGR of 0.37% over 3 years signals near-zero organic growth; the business is not compounding intrinsic value per share meaningfully
Operating margin of 5.5% and net margin of 4.5% are characteristic of commodity packaging, not a business with durable pricing power
Late discovery of DSC demand weakness (Q3 2025 guidance miss, visibility only in early October) questions management's forecasting competence and forward visibility
Goodwill/intangibles bloat from serial M&A (Vayner and prior deals) obscures true returns on tangible capital; reported ROIC likely overstates underlying economics
The Vayner integration opacity makes it impossible to independently validate the acquisition thesis — a Munger warning sign about accounting and disclosure quality

Michael Mauboussin — 🟡 watch · 52/100 · medium confidence

Silgan Holdings is a mature, capital-intensive packaging business where the ROIC/WACC spread is the central question. The company is applicable to expectations-investing analysis but presents a mixed picture: ROIC of 4.74% sits below the DCF-implied WACC of 7%, which is the most important single data point and a structural concern. The DCF intrinsic value ($64.31) implies ~39% upside, suggesting the market may be embedding pessimistic expectations — but I must ask whether those embedded expectations are actually too low, or whether the market is correctly pricing a thin spread. The moat is real but narrow: Silgan benefits from (1) meaningful customer switching costs in metal containers via long-term contracts (5–10 years) with blue-chip, investment-grade food companies — switching container suppliers mid-contract in capital-intensive food processing is genuinely costly; (2) scale economies in metal can manufacturing where fixed costs are substantial and plant utilization matters; and (3) some specialized formulation/dispensing capability in the Dispensing & Specialty Closures segment, particularly in fragrance/beauty. However, these moat sources score as Narrow, not Wide — packaging remains a competitively tendered commodity in many sub-segments, pricing power is constrained by pass-through structures, and organic revenue CAGR of only 0.37% over 3 years confirms the industry is not growing. The Vayner acquisition (mid-2024) complicates the quality assessment: management has a history of acquisition-led growth rather than organic compounding, which is a capital-allocation red flag — each deal must be evaluated at ROIC-accretive terms, and the opacity of Vayner's standalone P&L post-integration makes this impossible to verify from available data. On expectations: at P/FCF of 11.6x and P/E of 16.9x, the market is not demanding extraordinary performance — the implied growth in the DCF is just 2% (roughly revenue CAGR), which is modest. The bear case ($48/share) is barely above current price ($46.23), suggesting limited downside if base-rate growth holds. The bull case ($72.66) requires sustained FCF growth and multiple expansion. The key question is whether ROIC can migrate back above WACC as Vayner synergies mature, pet food capacity investments generate returns, and leverage declines from FCF deployment. At $450M guided FCF vs. $2.63B net debt, deleveraging is real but multi-year. Skill vs. luck: the 89-quarter dividend streak and consistent FCF generation suggest a disciplined operator, but the Q4 2025 guidance cut (late visibility on DSC weakness) raises process concerns. Management's consumer bifurcation narrative is plausible but unquantified — no segment exposure data provided, making the inside-view adjustment difficult. The distribution of outcomes: bull (30%) — ROIC inflects above WACC as Vayner integrates, pet food grows, leverage declines, stock reaches $60–65; base (45%) — ROIC stays near WACC, stock grinds to $52–58 on FCF yield; bear (25%) — consumer weakness extends, leverage constrains flexibility, ROIC stays below WACC, stock revisits $36–40. The fat tail risk is leverage combined with an extended consumer downcycle compressing FCF below $400M.

Key points

ROIC of 4.74% is below stated WACC of 7% — the spread is negative, which is the most critical quality flag; value creation requires sustained ROIC > WACC and there is no evidence of this currently
Moat is Narrow but real: switching costs via 5–10 year contracts with blue-chip food companies in metal containers; some scale economies in manufacturing; specialized dispensing capabilities in fragrance/beauty segment
Expectations embedded in price appear modest — P/FCF of 11.6x, 2% DCF growth assumption — meaning the bar for positive surprise is low; bear DCF ($48) is near current price providing limited downside
$450M guided 2026 FCF vs. $2.63B net debt enables meaningful deleveraging trajectory; strong FCF conversion (FCF margin 6.5%) is a genuine quality signal in a low-margin business
Revenue CAGR of only 0.37% over 3 years confirms this is a low-growth mature business; high-value dispensing segment growing double-digits organically is a bright spot but its scale relative to total is unclear
Acquisition-heavy growth strategy (Vayner, prior M&A) creates ROIC dilution risk; inability to isolate Vayner P&L post-integration is an information gap that prevents quality assessment of capital allocation discipline

Red flags

ROIC (4.74%) is materially below WACC (7%), meaning at current economics the business is destroying value on an incremental basis — the spread must improve for quality thesis to hold
Organic revenue growth near zero (0.37% CAGR) means the business depends on M&A or margin expansion for EPS growth; high acquisition pace raises the risk of diminishing ROIC on each successive deal
Q4 2025 guidance cut revealed late visibility into DSC segment weakness — management only had clear forecast in early October for Q4 decline, raising questions about process quality and predictive discipline
Debt-to-equity of 1.63x and $3.7B long-term debt constrains capital allocation flexibility; any FCF shortfall extends the deleveraging timeline and limits buyback or reinvestment optionality
PEG ratio of 45.78 is anomalously high, reflecting near-zero earnings growth relative to multiple — a warning that the current P/E is not supported by growth rates
Consumer bifurcation risk in DSC segment is unquantified — no disclosure of % of DSC revenue exposed to lower-income personal care/home care, making probability-weighted scenario analysis imprecise

Chuck Akre — 🔴 avoid · 32/100 · high confidence

Silgan Holdings fails on the most critical legs of the three-legged stool as I apply it. The business is fundamentally a packaging manufacturer — metal cans, dispensing closures, custom containers — a capital-intensive, low-margin, largely commoditized industrial business. Let me go through each leg carefully. (1) Extraordinary business: ROIC is 4.74% and ROE is 12.7%, but this ROE is significantly leveraged (debt/equity of 1.63x, net debt of ~$2.6B against equity of $2.27B). The underlying unleveraged business economics are weak — operating margin of only 5.5%, net margin of 4.5%, FCF margin of 6.5%. These are not the hallmarks of an extraordinary franchise. ROIC at 4.74% is materially below even a modest cost of capital estimate; this business is destroying economic value, not creating it. The fact that 80%+ of the DCF value resides in the terminal value underlines how dependent the investment thesis is on assumed perpetual growth — itself a sign of an underpowered near-term business. (2) Management quality: The 89-quarter dividend streak shows some capital discipline, and management has been reasonably candid about Q4 2025 weakness. However, ROE of 12.7% and ROIC of 4.74% represent sustained mediocrity over years. Revenue CAGR is essentially flat (0.37% over 3 years). The Vayner acquisition adds leverage and integration risk without yet demonstrating high-return reinvestment. One retail holder noted +3.5% total return since 2021 — consistent with the mediocre compounding picture. CEO pay relative to these outcomes raises alignment concerns. (3) Reinvestment runway: This is the most critical failure. Packaging — particularly metal cans — is a mature, slow-growth market. Revenue CAGR of ~0.4% for three years confirms this. Capex is $307M against OCF of $730M (capex/OCF of ~42%), reflecting meaningful capital intensity. Management's own guidance implies only 2% earnings growth in 2026. There is no credible high-return reinvestment runway visible. FCF per share may grow modestly as debt declines, but this is financial de-levering, not compounding in the Akre sense. The stock trades at 11.6x price/FCF and shows DCF upside to ~$64, which is interesting but not my test — I need compounding economics, not just DCF undervaluation. This is a business that is more of a value/income play than a compounder.

Key points

ROIC of 4.74% is below cost of capital — business is not earning above-normal returns on incremental capital, the foundational requirement
ROE of 12.7% is leveraged (D/E 1.63x, net debt $2.6B); without leverage, underlying returns are poor
Revenue CAGR of 0.37% over 3 years and management guiding only ~2% EPS growth in 2026 confirm mature, low-growth market with no reinvestment runway
Capital intensity is significant: capex of $307M (~42% of operating cash flow), operating margin only 5.5%
Management has been relatively candid (acknowledged Q4 miss, bifurcated demand), and 89-quarter dividend streak shows some capital discipline — partial credit on integrity
DCF suggests ~39% upside to $64, and price/FCF of 11.6x is cheap in isolation, but cheapness is not the Akre criterion
Metal cans and dispensing closures are largely commoditized; pricing power is limited and competitive advantage is not durable in the franchise sense I require

Red flags

ROIC (4.74%) is materially below any reasonable WACC estimate — economic value destruction on incremental capital
ROE entirely dependent on leverage; strip out debt and the business economics are weak
Mature, stagnant revenue growth (0.37% 3-year CAGR) — no reinvestment runway at high rates of return
Heavy gross debt ($3.7B long-term) acquired partly via Vayner acquisition — leverage elevated post-M&A with integration still ongoing
Operating income figure in fundamentals block shows $359M for 2019 vs. current period — possible data inconsistency flagged, but regardless, margins are thin
PEG of 45.78 reflects near-zero growth relative to any earnings multiple — confirms no compounding growth thesis
No evidence of meaningful insider ownership or owner-operator alignment from available data
Consumer cyclical sector classification and packaging industry are inherently capital-intensive, low-moat — structural mismatch with Akre criteria

Walter Schloss — 🔴 avoid · 32/100 · high confidence

Silgan Holdings fails my core criteria on the two most important dimensions: balance sheet strength and price-to-book. The company carries $3.715B in long-term debt against $2.274B in stockholders' equity, giving a debt-to-equity ratio of 1.63x — this is a heavily leveraged balance sheet, exactly what I fear most. A packaging company cannot survive a prolonged downturn or recession if creditors can force a fire sale before value is realized. The equity base is also substantially inflated by intangibles and goodwill from the Vayner and other acquisitions; tangible book value would be materially lower than the reported $2.274B in equity, making the price-to-tangible-book almost certainly well above 2x and possibly negative in tangible terms. At $46.23 and a price-to-book of 2.15x reported book, there is no margin of safety in the assets. The stock is also trading at its 52-week high ($46.23 equals the reported 52w high in the price block), the precise opposite of what I require — I buy things that are beaten down, not things at their highs. The business does have some Schloss-like qualities: it is a long-operating industrial manufacturer, it pays a sustained dividend (89-quarter streak), revenue is real and tangible (metal cans, closures), and FCF of $422M is substantial. The low beta (0.71) and P/S of 0.75x are modestly favorable. But none of these offset the fundamental problem: I need to buy assets cheap with a fortress balance sheet. Here, I am paying above book for a debt-laden company trading at peak price. The DCF implies 39% upside, but my method does not rely on DCF optimism — I rely on hard assets. If earnings disappoint further (as they did in Q4 2025, cutting guidance materially) and debt service consumes FCF, equity holders are vulnerable. This is a decent business at a mediocre price with a dangerous balance sheet — not a Schloss bargain.

Key points

Price-to-book of 2.15x reported equity; tangible book likely negative or near zero after stripping intangibles/goodwill from acquisitions (Vayner etc.), so true price-to-tangible-book could be extremely high
Long-term debt of $3.715B versus stockholders' equity of $2.274B yields D/E of 1.63x — heavy leverage is my primary red flag; this removes the margin of safety in the balance sheet
Stock is trading at its 52-week high ($46.23 = reported 52w high), not beaten down or out of favor — I require distress and disfavor, not momentum
Current ratio of 1.22x is modest but not alarming; $1.08B cash provides some liquidity buffer, but net debt of $2.63B is substantial
89-quarter dividend streak is a positive signal of balance sheet durability and management commitment to shareholders
Operating history is long and simple — metal cans and closures for food/beverage/personal care — the kind of business I can read from filings
Revenue CAGR of only 0.37% over 3 years signals stagnant top-line growth, which is consistent with a value situation but does not compensate for leverage risks

Red flags

Debt-to-equity of 1.63x is far above my comfort zone; I prefer little or no long-term debt — $3.715B LTD is disqualifying for my framework
Stock at 52-week high — Schloss bought at lows, not highs; no margin of safety in price versus recent history
Price-to-book of 2.15x on reported equity; tangible book likely far lower given M&A-driven goodwill and intangibles on balance sheet
Thesis heavily depends on FCF generation, earnings recovery, and Vayner integration success — all forward-looking, not verifiable from hard assets today
Management Q4 2025 guidance cut of $25M headwind shows forecast unreliability; late visibility into DSC segment weakness raises credibility concerns
ROIC of 4.74% is below cost of capital (WACC 7%), meaning the business destroys value on invested capital at current returns
No data on insider ownership or insider buying — a key Schloss requirement for alignment; cannot confirm management has skin in the game

Terry Smith (Fundsmith) — 🔴 avoid · 32/100 · high confidence

Silgan Holdings is a profitable, cash-generative industrial packaging business, so the quality screen is applicable — but it fails most of Fundsmith's core criteria. ROCE sits at a meagre 4.7% (reported ROIC), well below any reasonable cost of capital hurdle and dramatically below Fundsmith's 20%+ standard. Operating margins are thin at 5.5%, reflecting the commodity-adjacent nature of metal cans and plastic closures. The business is capital-intensive: capex consumed $307M against $423M FCF (capex/OCF ~42%), leaving genuine free cash flow per share modest relative to the asset base. The balance sheet carries $3.7B of long-term debt against $2.3B of equity (D/E 1.63x, net debt ~$2.6B), a leverage posture Smith explicitly disqualifies. Silgan has been a serial acquirer — Dispensing & Specialty Closures built heavily via M&A including Vayner (closed mid-2024, debt-funded), with large goodwill on the balance sheet and management's own admission of difficulty isolating organic vs. inorganic performance. Reported earnings vs. FCF conversion looks acceptable on the surface (FCF $423M vs. net income $288M), but adjusted EPS metrics abound and the gap partly reflects D&A on acquisition goodwill rather than genuine earnings quality. Revenue CAGR is essentially flat at 0.4% over three years, offering no visible reinvestment runway with high incremental returns. The DCF implies ~39% upside to intrinsic value ($64.31 vs. $46.23), and at 11.6x price-to-FCF the valuation is not egregiously expensive — but Fundsmith does not own mediocre businesses cheaply; the valuation is a secondary concern when the quality hurdle is not met. Demand is somewhat recurring (long-term metal container contracts, ~90% under 5-10 year agreements), and the 89-quarter dividend streak signals financial discipline, but these positives cannot overcome structural deficiencies in returns on capital, margins, and balance sheet quality.

Key points

ROIC of 4.7% is far below Fundsmith's 20%+ ROCE requirement — capital is not being deployed at value-creating rates
Operating margin of 5.5% and net margin of 4.5% indicate a commodity-like business lacking durable pricing power
Serial debt-funded acquisitions (Vayner 2024, prior DSC roll-ups) inflate goodwill and obscure true organic returns — a core Fundsmith disqualifier
Net debt of ~$2.6B against equity of $2.3B represents balance sheet fragility inconsistent with Fundsmith's self-funding preference
Capex intensity is high: $307M capex on $730M operating cash flow (~42%), limiting genuine capital-light compounding
Revenue essentially flat (0.4% CAGR over 3 years) — no visible high-return reinvestment runway
Long-term metal container contracts with investment-grade customers provide some demand resilience, a partial positive

Red flags

Debt/equity of 1.63x and $3.7B long-term debt — Smith's most explicit disqualifier
Serial M&A growth strategy (Vayner, prior acquisitions) with management unable to isolate organic DSC performance post-integration
ROIC of 4.7% implies capital destruction relative to any plausible WACC of 7%+
Pervasive 'adjusted' EPS metrics in guidance and analyst coverage, masking integration costs
Heavy capex relative to OCF makes the business capital-intensive rather than asset-light
Revenue CAGR near zero — not a compounder by any definition
Q4 2025 earnings miss with late management visibility into demand weakness raises governance/forecasting concerns

Stanley Druckenmiller — 🔴 avoid · 28/100 · high confidence

SLGN fails the Druckenmiller framework on almost every dimension that matters to me. My process demands a clear directional earnings inflection — an accelerating second derivative where I can see forward estimates moving UP with conviction and a catalyst the market hasn't priced. What I see instead is: (1) revenue CAGR of 0.4% over 3 years — essentially a flat-to-stagnant top line; (2) 2026 full-year adjusted EPS guidance of $3.73–$3.93, representing roughly 2% growth at the midpoint vs. $3.72 in 2025 — not an inflection, barely a rounding error; (3) management that just cut Q4 2025 guidance materially ($25M headwind) and was caught flat-footed in late September on DSC volume weakness, suggesting poor forward visibility not a clear catalyst trajectory; (4) ROIC of only 4.7% with operating margins at 5.5% — these are not the metrics of a business generating above-cost-of-capital returns that would attract a momentum-of-earnings bid; (5) debt-to-equity of 1.63x and $3.7B long-term debt post-Vayner, meaning the balance sheet is not clean and earnings direction is hostage to deleveraging discipline; (6) the stock is trading AT its 52-week high of $46.23 with beta of 0.71 — no momentum leadership, no relative strength punch, a defensive plod. On the liquidity/macro front: Silgan is a packaging manufacturer with 0.7 beta, deeply cyclical exposure to consumer staples packaging, no leverage to a policy/rate cycle inflection in a way that creates a convex payoff. FCF at $422M and price/FCF of 11.6x tells you this is a reasonable value but not a momentum trade. The DCF intrinsic of $64/share and 39% upside is interesting and the DCF assumptions are defensible (WACC 7%, 2% growth — conservative), but that's a valuation story, not a catalyst story. I don't buy stocks because they're cheap; I buy them when the earnings are going somewhere fast and the tape agrees. Neither condition is met here. The tape just reached a 52-week high at $46.23 but on the back of 2% EPS growth and a consumer bifurcation narrative that management itself cannot fully quantify — that's not the kind of breakout I want to ride. The 89-quarter dividend streak is admirable but is income investor territory, not where I operate.

Key points

Revenue CAGR near zero (0.4% over 3 years) — no top-line momentum to drive an earnings inflection thesis
2026 adjusted EPS guidance of $3.73–$3.93 implies ~2% growth — no acceleration visible, second derivative is flat at best
Management caught off-guard by Q4 2025 DSC volume weakness in late September, raising forward visibility concerns critical to timing a directional bet
ROIC of 4.7% and operating margin of 5.5% — returns well below a premium franchise, limiting the earnings power story
$3.7B long-term debt post-Vayner creates balance sheet overhang; deleveraging path (though clear) caps capital return velocity
Low beta (0.71) and sector classification as Consumer Cyclical packaging — limited leverage to macro/policy cycle tailwinds that power a Druckenmiller-style macro trade
Price AT 52-week high but no relative outperformance thesis; a defensive name in a market where I want leadership

Red flags

No clear earnings inflection — 2% forward EPS growth is not the second derivative turning sharply up
Consumer bifurcation demand headwind in DSC (personal care, home care) unquantified and without clear recovery catalyst timing
Late visibility into Q4 2025 miss signals weak forecasting apparatus — makes thesis management impossible
Leverage elevated at 1.63x D/E with $3.7B LTD; thesis dependent on successful deleveraging adds conditionality
PEG ratio of 45.78 implies growth not remotely justifying current earnings multiple on a forward momentum basis
Price/FCF of 11.6x is value territory but the absence of earnings acceleration means no re-rating catalyst
No identifiable 'why now' catalyst — Vayner already integrated, no new product cycle, no policy tailwind, no sector rotation driver specific to SLGN

Philip Fisher — 🔴 avoid · 28/100 · high confidence

Silgan Holdings is a packaging and containers business — a mature, capital-intensive, largely commodity-adjacent manufacturing company. While it has some differentiated product lines (dispensing and specialty closures, including fragrance/beauty applications), the fundamental growth profile does not meet Fisher's bar. Revenue CAGR is a meager 0.37% over three years, far below any definition of 'above-industry organic growth.' Operating margin of 5.54% is thin and undistinguished. ROIC at 4.74% is below most reasonable estimates of cost of capital, meaning the company is actually destroying value on incremental investment. There is no evidence of meaningful R&D spend or a product pipeline that converts science into new markets. Growth in the dispensing segment is largely acquisition-driven (Vayner, acquired mid-2024) rather than organic compounding of a proprietary franchise. Management guided only ~2% EPS growth for 2026 — and even that was achieved after lowering the bar following a Q4 2025 miss. This is the antithesis of the compounding growth engine Fisher sought. The one Fisher-adjacent positive is management candor: the Q3 2025 call acknowledged DSC weakness, quantified headwinds ($25M), and management maintained FCF guidance through proactive inventory reduction — that is relatively honest stewardship. But honesty alone does not create a growth franchise. The 89-quarter dividend streak, while admirable for income investors, is exactly the capital allocation posture Fisher warned against — paying out capital rather than reinvesting internally at high returns. Debt/equity of 1.63x with ROIC below WACC means leverage is amplifying mediocre returns. There is no scuttlebutt case here for an R&D-driven product moat, no visible new market runway, and no evidence of the kind of sales organization that drives durable share gains in expanding markets.

Key points

Revenue CAGR of only 0.37% over 3 years — essentially zero real organic growth, disqualifying under Fisher's core criterion
Operating margin 5.54% and ROIC 4.74% — below cost of capital, signaling value destruction on incremental capital deployed
Dispensing segment growth is acquisition-driven (Vayner, 2024) not organic product innovation; Fisher explicitly disfavors bought growth
No evidence of meaningful R&D investment or a product pipeline converting research into new markets
2026 guidance implies only ~2% EPS growth — management itself signals no acceleration in the organic franchise
89-quarter dividend streak signals capital returned rather than compounded internally at high returns — the opposite of Fisher's long-term reinvestment ethos
Management candor is a relative positive: transparent on Q4 2025 miss, quantified headwinds, maintained FCF guidance through cost actions

Red flags

Revenue growth is flat/stalling: 0.37% CAGR over 3 years with volume declines in key DSC segments in 2025
ROIC of 4.74% is almost certainly below WACC (~7% per DCF model), meaning serial M&A and capex is destroying shareholder value
No R&D pipeline or product-driven market expansion evident anywhere in filings or management commentary
Debt/equity of 1.63x with below-WACC returns creates a dangerous combination — leverage amplifying mediocre economics
Dispensing segment growth guided at 'at least mid-single-digit' organic for 2026 — tepid versus Fisher's threshold for above-industry compounding
Consumer bifurcation narrative is demand-side excuse masking structural margin and volume pressure in personal care/home care
PEG of 45.78 reflects near-zero growth at a non-trivial earnings multiple — the worst of both worlds for a growth lens

Fact base appendix

Price

last_close: 46.23
as_of: 2026-06-26
high_52w: 46.23
low_52w: 46.23
pct_below_52w_high: 0.0

Fundamentals

last_price: 46.23
market_cap: 4885575212
fifty_two_week_low: 35.68
fifty_two_week_high: 57.04
beta: 0.707
change_pct: 1.98544
currency: USD
sector: Consumer Cyclical
industry: Packaging & Containers
price_source: fmp_profile
bars: 1
entity: SILGAN HOLDINGS INC
fiscal_year: 2025
revenue: 6483166000
revenue_period: 2025-12-31
net_income: 288403000
net_income_period: 2025-12-31
operating_income: 359486000
operating_income_period: 2019-12-31
operating_cash_flow: 729841000
operating_cash_flow_period: 2025-12-31
capex: 307092000
capex_period: 2025-12-31
total_assets: 9397083000
total_assets_period: 2025-12-31
current_assets: 2991918000
current_assets_period: 2025-12-31
current_liabilities: 2451869000
current_liabilities_period: 2025-12-31
stockholders_equity: 2274301000
stockholders_equity_period: 2025-12-31
cash_and_equivalents: 1080659000
cash_and_equivalents_period: 2025-12-31
long_term_debt: 3715216000
long_term_debt_period: 2025-12-31
shares_outstanding: 105441971
operating_margin: 0.0554
net_margin: 0.0445
roe: 0.1268
debt_to_equity: 1.6336
current_ratio: 1.2203
roic: 0.0474
free_cash_flow: 422749000
fcf_margin: 0.0652
pe_ratio: 16.94
price_to_fcf: 11.56
price_to_sales: 0.75
revenue_cagr: 0.0037
revenue_cagr_years: 3
fundamentals_source: edgar_companyfacts
price_to_book: 2.15
earnings_yield: 0.0478
peg: 45.78

Filings reviewed

8-K (2026-05-29) https://www.sec.gov/Archives/edgar/data/849869/000162828026039148/slgn-20260526.htm
8-K (2026-05-12) https://www.sec.gov/Archives/edgar/data/849869/000162828026034164/slgn-20260512.htm
10-Q (2026-05-06) https://www.sec.gov/Archives/edgar/data/849869/000162828026031008/slgn-20260331.htm
10-K (2026-02-26) https://www.sec.gov/Archives/edgar/data/849869/000162828026012202/slgn-20251231.htm
10-Q (2025-11-05) https://www.sec.gov/Archives/edgar/data/849869/000162828025049324/slgn-20250930.htm
10-K (2025-02-27) https://www.sec.gov/Archives/edgar/data/849869/000084986925000029/slgn-20241231.htm

Other sources

[news] Earnings call transcript: Silgan Holdings Inc. delivers strong Q1 2026 results - Investing.com
[news] Analysts Estimate Silgan Holdings (SLGN) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
[news] Silgan Holdings Extends Long-Running Quarterly Dividend Streak - The Globe and Mail
[news] Silgan Announces Fourth Quarter and Full Year 2025 Results; Expects Continued Growth in 2026 - Business Wire
[news] Silgan Holdings (NYSE: SLGN) extends 89-quarter dividend streak - Stock Titan
[news] RBC Capital raises Silgan Holdings stock price target on Q1 beat - Investing.com
[news] SLGN Forecast — Price Target — Prediction for 2027 - TradingView
[news] SILGAN HOLDINGS INC ($SLGN) CEO 2025 Pay Revealed | SLGN Stock News - Quiver Quantitative
[news] Silgan Holdings: Strong Cash Flows Will Reduce Net Debt Fast (NYSE:SLGN) - Seeking Alpha
[news] How Silgan’s New Dividend and Lower Input Costs At Silgan Holdings (SLGN) Has Changed Its Investment Story - Yahoo Finance
[news] Silgan Holdings (SLGN) Rides Packaging Rally as Dividend Yield Draws Scrutiny of Its Risk-Reward Balance - Sahm
[news] Silgan Holdings Inc (SLGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
[news] Silgan Holdings Inc. Actuals & Estimates (NYSE:SLGN) - TradingView
[news] Silgan Holdings Inc. Actuals & Estimates (NYSE:SLGN) - TradingView
[news] Is Silgan Holdings Inc. (SLGN) A Good Stock To Buy Now? - Yahoo Finance
[news] Is Silgan Holdings Inc. (SLGN) A Good Stock To Buy Now? - Insider Monkey
[news] Silgan to Release First Quarter 2026 Earnings Results on April 29, 2026 - Business Wire
[discussion] Wall St is expecting 0.96 EPS for $SLGN Q2 [Reporting 07/29 BMO] http://www.estimize.com/intro/slgn?
[discussion] $SLGN Q1 '26 Earnings Results & Recap

Silgan increased its full-year 2026 adjusted diluted

[discussion] $SLGN Purchased this pig on 1/5/2021. I’m up 3.5%.

Based on the last earnings call you’d think th

[discussion] $SLGN Share Price: $40.91

Contract Selected: Nov 20, 2026 $35 Calls

Buy Zone: $4.67 – $5.78 Target

[discussion] [Bullish] Nice potential on the $SLGN setup, with multiple bottoms already put in at the $36-37 area
[discussion] [Bullish] $SLNG same LNG topic as $ANNA, tiny float 3.32 MM, it 1H or 1D time frames chart pattern s
[discussion] $SLGN https://clarval.com/stock/SLGN
[discussion] $SLGN Share Price: $47.98

Contract Selected: Aug 21, 2026 $50 Calls

Buy Zone: $0.98 – $1.21 Target

[discussion] $SLGN interesting on WL, strong value play
[discussion] $SLGN Share Price: $48.41

Contract Selected: Aug 21, 2026 $50 Calls

Buy Zone: $1.32 – $1.63 Target

[discussion] $SLGN reported 0.67 EPS and 1,469 revenue for Q4. http://www.estimize.com/intro/slgn?chart=historica
[discussion] $SLGN Q4 '25 Earnings Results & Recap

Silgan expects full year 2026 adjusted diluted EPS be

[discussion] $SLGN Current Stock Price: $43.25 Contracts to trade: $45.0 SLGN Feb 20 2026 Call Entry: $0.60 Exit:
[discussion] $SLGN Current Stock Price: $38.13 Contracts to trade: $40 SLGN Dec 19 2025 Call Entry: $5.04 Exit: $
[discussion] Truist Securities updates rating for Silgan Hldgs ( $SLGN ) to Buy, target set at 59 → 63.
[earnings_call] Silgan Holdings Inc SLGN Q3 2025 Earnings Call

Generated 2026-07-17T20:50:07 · est. cost $1.42

What each investor thinks

AI & Disruption Referee (Christensen-style) Referee

pass · 78

Valuation Referee (Damodaran-style) Referee

pass · 72

Bruce Greenwald Value

pass · 72

Forensic Short-Seller (Chanos/Einhorn-style) Referee

pass · 62

Joel Greenblatt Value

watch · 58

Howard Marks Risk

watch · 58

Ray Dalio Risk

watch · 55

Benjamin Graham Value

watch · 55

Warren Buffett Quality

watch · 52

Seth Klarman Value

watch · 52

Peter Lynch Growth

watch · 52

Charlie Munger Quality

watch · 52

Michael Mauboussin Quality

watch · 52

Chuck Akre Quality

avoid · 32

Walter Schloss Value

avoid · 32

Terry Smith (Fundsmith) Quality

avoid · 32

Stanley Druckenmiller Risk

avoid · 28

Philip Fisher Growth

avoid · 28

Want this on a name you own?Send a ticker; we convene the full council on it.

Request Analysis →

Silgan Holdings Inc

SILGAN HOLDINGS INC (SLGN) — Council Assessment

🟡 WATCH · Score 54/100 · medium confidence

360 narrative — news & sentiment digest

SLGN Investment Briefing

Management Commentary (Q3 2025 Earnings Call)

Recent Developments

Bull Narrative

Bear Narrative

Retail Sentiment

Caveats

Bull case

Bear case

Dissent — where the council disagrees

Key risks

Catalysts

DCF valuation (finance-expert model)

Short-sell evaluation

Council scorecard

Member reasoning

AI & Disruption Referee (Christensen-style) — 🟢 pass · 78/100 · high confidence

Valuation Referee (Damodaran-style) — 🟢 pass · 72/100 · medium confidence

Bruce Greenwald — 🟢 pass · 72/100 · medium confidence

Forensic Short-Seller (Chanos/Einhorn-style) — 🟢 pass · 62/100 · medium confidence

Joel Greenblatt — 🟡 watch · 58/100 · medium confidence

Howard Marks — 🟡 watch · 58/100 · medium confidence

Ray Dalio — 🟡 watch · 55/100 · medium confidence

Benjamin Graham — 🟡 watch · 55/100 · medium confidence

Warren Buffett — 🟡 watch · 52/100 · medium confidence

Seth Klarman — 🟡 watch · 52/100 · medium confidence

Peter Lynch — 🟡 watch · 52/100 · medium confidence

Charlie Munger — 🟡 watch · 52/100 · medium confidence

Michael Mauboussin — 🟡 watch · 52/100 · medium confidence

Chuck Akre — 🔴 avoid · 32/100 · high confidence

Walter Schloss — 🔴 avoid · 32/100 · high confidence

Terry Smith (Fundsmith) — 🔴 avoid · 32/100 · high confidence

Stanley Druckenmiller — 🔴 avoid · 28/100 · high confidence

Philip Fisher — 🔴 avoid · 28/100 · high confidence

Fact base appendix

AI & Disruption Referee (Christensen-style) Referee

Valuation Referee (Damodaran-style) Referee

Bruce Greenwald Value

Forensic Short-Seller (Chanos/Einhorn-style) Referee

Joel Greenblatt Value

Howard Marks Risk

Ray Dalio Risk

Benjamin Graham Value

Warren Buffett Quality

Seth Klarman Value

Peter Lynch Growth

Charlie Munger Quality

Michael Mauboussin Quality

Chuck Akre Quality

Walter Schloss Value

Terry Smith (Fundsmith) Quality

Stanley Druckenmiller Risk

Philip Fisher Growth